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Effect of Anti-vascular Endothelial Growth Factor Antibody on the 
Survival of Cultured Retinal Ganglion Cells
Ji Min Lee, Hyoung Won Bae, Sang Yeop Lee, Gong Je Seong, Chan Yun Kim
Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
Purpose: To investigate the effects of anti-vascular endothelial growth factor (VEGF) antibody on the survival of 
retinal ganglion cell (RGC)-5 cells differentiated with staurosporine under oxidative stress. 
Methods: We used real-time polymerase chain reaction and Western blot to confirm the expression of VEGF, 
VEGF receptor (VEGFR)-1 and VEGFR-2 in RGC-5 cells differentiated with staurosporine for 6 hours. The dif-
ferentiated RGC-5 cells were treated with 800 μM hydrogen peroxide (H2O2) for 24 hours to induce oxidative 
stress. Then, the survival rate of RGC-5 was confirmed by lactate dehydrogenase assay at each concentra-
tion (0, 0.01, 0.1, and 1 mg) using bevacizumab as the anti-VEGF antibody. The expression of VEGF, VEGFR-1, 
and VEGFR-2 was confirmed using real-time polymerase chain reaction. 
Results: VEGF, VEGFR-1, and VEGFR-2 were all expressed in differentiated RGC-5 cells. When RGC-5 cells 
were simultaneously treated with bevacizumab and 800 μM H2O2, survival of RGC-5 decreased with bevaci-
zumab concentration. VEGF expression in RGC-5 cells increased with increasing concentration of bevacizum-
ab. Similar patterns were observed for VEGFR-1 and VEGFR-2, but the degree of increase was smaller than 
that for VEGF. 
Conclusions: When bevacizumab was administered to differentiated RGC-5 cells, the cell damage caused by 
oxidative stress increased. Therefore, given these in vitro study results, caution should be exercised with bev-
acizumab treatment. 
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The hypothesis that a specific substance acts on neovas-
cularization in retinal diseases was first proposed in 1956 
[1] and it was determined that vascular endothelial growth 
factor (VEGF) is increased in the oxidative stress environ-
ment of the retina [2-5]. VEGF is a 46-kDa molecular 
weight glycoprotein that binds to receptors on the surface 
of vascular endothelial cells to proliferate and increase 
capillary permeability [6]. Previously, it was thought that 
VEGF function was restricted to endothelial cells. Howev-
er, in recent studies, VEGF was shown to promote the de-
velopment and maturation of neural tissues, including the 
retina [7]. In the normal development of the retina, VEGF 
acts as an essential factor in the production and survival 
and function of cells [8,9]. However, VEGF has been im-
plicated in the development of neovascularization in vari-
ous retinal vascular diseases such as exudative age-related 
macular degeneration, proliferative diabetic retinopathy, 
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macular edema of retinal vein occlusion, and retinopathy 
of prematurity. In addition, it has been shown that the ele-
vated level of VEGF in these diseases plays a key role in 
the progression of disease [2,10,11]. Recently, treatment 
with the anti-VEGF antibody bevacizumab has been wide-
ly used for these diseases in the field of ophthalmology, 
and positive treatment effects have been reported in many 
eye diseases that cause blindness [12,13]. However, since 
angiogenesis is an important mechanism that protects tis-
sues against various ischemic injuries, bevacizumab ad-
ministration for the inhibition of angiogenesis potentially 
has unexpected harmful effects on the tissue [8]. Previous 
studies have reported the safety and side effects of bevaci-
zumab treatment [14]. One of the studies reported that bev-
acizumab injection resulted in the death of retinal ganglion 
cells (RGCs) in an animal model [15]. In this study, we in-
vestigated the effects of bevacizumab on the survival of 
retinal ganglion cells cultured in a hypoxic environment 
through experimental methods in order to establish a basis 
for the safe and effective use of anti-VEGF antibody thera-
py in various ophthalmic diseases. 
Materials and Methods
Growth of cell lines
Differentiation of RGC-5 cells was used in this study. 
The RGC-5 cell line selectively retained the retinal gangli-
on cells in the mouse and was infected with the R-virus to 
maintain retinal ganglion cell characteristics [16,17]. In a 
previous study [18], staurosporine (Sigma, Poole, UK) was 
used at a concentration of 1 μg for a minimum of 6 hours 
to reach the final differentiation level of the RGC-5 cell 
line. In the present study, RGC-5 cells were treated with 1 
μg staurosporine for 6 hours as well. 
Identification of VEGF, VEGF receptor (VEGFR)-1 and 
VEGFR-2 expression in differentiated RGC-5 cell lines 
The expression of VEGF, VEGFR-1, and VEGFR-2 was 
assessed by real-time polymerase chain reaction (PCR) and 
Western blot (Table 1 and Fig. 1) after culturing RGC-5 
cells differentiated using the above method. 
cDNA synthesis 
cDNA was synthesized from the extracted total RNA 
according to the manufacturer’s protocol using the Super-
Script III First-Strand Synthesis System for real-time PCR 
(Gibco, Grand Island, NY, USA). Briefly, cultured RGC-5 
cells were floated with trypsin and total RNA was extract-
ed using RNeasy mini kit (Qiagen, Valencia, CA, USA). A 
combination of 1 μL of extracted total RNA, 1 μL of 50 
μM oligo (dT), 1 μL of 10 mM deoxynucleoside triphos-
phate (dNTP) mix and diethyl pyrocarbonate (DEP-
C)-treated water for a total volume of 10 μL was incubated 
at 65°C for 5 minutes. The mixture was then put on ice for 
1 minute to stop the reaction. Next, 2 μL of 10 × reverse 
transcription (RT) buffer, 4 μL of 25 mM MgCl2, 2 μL of 
0.1 M dithiothreitol (DTT), 1 μL of RNaseOUT (40 U/μL) 
and 1 μL of SuperScript III RT (200 U/μL) was added for a 
total volume of 20 μL. Thereafter, the cells were incubated 
at 50°C for 50 minutes and incubated at 85°C for 5 minutes 
to stop the reaction, and then the tubes were placed on ice. 
Table 1. Primer sequences for real-time PCR
Gene name Sequence
VEGF-A (172 bp) Forward: 5’-gcccatgaagtggtgaagtt-3’
Reverse: 5’-actccagggcttcatcattg-3’
VEGFR-1 (157 bp) Forward: 5’-tttatcagcgtgaagcatcg-3’
Reverse: 5’-ccgaatagcgagcagatttc-3’
VEGFR-2 (129 bp) Forward: 5’-acagttcccagagtggttgg-3’
Reverse: 5’-gtcactgacagaggcgatga-3’
PCR = polymerase chain reaction; VEGF = vascular endothelial 
growth factor; VEGFR = VEGF receptor.
Fig. 1. Expression of vascular endothelial growth factor (VEGF), 
VEGF receptor (VEGFR)-1 and VEGFR-2 assessed by real-time 
polymerase chain reaction. VEGF, VEGFR-1, and VEGFR-2 are 
all expressed in differentiated retinal ganglion cell-5 cells. 
Ladder VEGF VEGFR-1 VEGFR-2 ß-actin negative control
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The reaction mixture was collected by light centrifugation 
and 1 μL of RNase H was added and incubated at 37°C for 
20 minutes to remove residual RNA. The resulting cDNA 
was stored at –20°C until further processing. 
Real-time PCR
Real-time PCR was performed using the QuantiTect 
SYBR Green PCR kit (Qiagen). A mixture of 100 ng of 
cDNA, 2 μL of 20 μM primers, 25 μL of master mix, and 
DEPC-treated water was added to each sample to make a 
50 μL mixture. The primer sequences are listed in Table 1. 
Each primer product was identified via melting curve 
analysis. The temperature conditions of the amplification 
process are as follows. Cycle 1, 95°C for 3 minutes; cycle 2 
(50 cycles; step 1, 95°C for 10 seconds; step 2, 55°C for 45 
seconds); cycle 3, 95°C for 1 minute; cycle 4, 55°C for 1 
minute; cycle 5 (80 cycles; step 1, 55°C for 10 seconds; step 
2, increase set point temperature after 2nd cycle by 0.5°C). 
Each mRNA level was calculated using the 2-∆Ct method 
based on the Ct value using β-actin as the reference house-
keeping gene.
Western blot
Sodium dodecyl sulfate polyacrylamide gel electropho-
resis was performed with 10%–15% sodium dodecyl sul-
fate-polyacrylamide gel and 50 μg of cell lysate was loaded 
in each well. After electrophoresis, the cells were elec-
tro-transferred to Immobilon-P transfer membrane (Milli-
pore, Billerica, MA, USA) under 200 mA for 2 hours. 
Three percent of BSA (AMRESCO, Solon, OH, USA) was 
used to inhibit nonspecific binding. After that, the primary 
antibody was added, reacted at room temperature for 1 
hour, washed and secondary antibody was used. One of 
the ECL peroxidase-labeled anti-rabbit (Amersham, Pisca-
taway, NJ, USA) or ECL peroxidase-labeled anti-mouse 
(Amersham) was selected for the primary antibody host, 
and then sensitized using Amersham ECL Western Blot-
ting Detection Reagents (Amersham).
Induction of oxidative stress and evaluation of cell 
survival
The differentiated RGC-5 cells were treated with H2O2 
(800 μM) for 24 hours to induce oxidative stress. Cell via-
bility was assessed using lactate dehydrogenase (LDH) as-
say. The amount of LDH was measured via colorimetric 
assay (Calbiochem-Novabiochem, San Diego, CA, USA), 
and whole cells were frozen. In comparison with the 
amount of LDH measured after death, the degree of de-
struction was evaluated. Serial dilutions of commercially 
available bevacizumab (Avastin; Genentech, San Francis-
co, CA, USA) were performed to obtain treatment concen-
trations of 0.01, 0.1, and 1 mg/mL.
Statistical analysis
Data are expressed as the mean ± standard deviation of 
at least three different experiments performed from sepa-
rate cell preparations, and at least triplicate determinations 
were performed for each experiment. Statistical tests to 
determine the difference between groups were performed 
by Mann-Whitney U-test using SPSS ver. 18.0 (SPSS Inc., 
Chicago, IL, USA). A p-value of less than 0.05 was consid-
ered statistically significant.
Results
Effect of bevacizumab on the survival of RGC-5 cell 
line under oxidative stress
Oxidative stress was induced in RGC-5 cells treated for 
24 hours using 800 μM H2O2. At that time, the RGC-5 
cells were simultaneously treated with the anti-VEGF anti-
body, bevacizumab (0, 0.01, 0.1, and 1 mg), and the effect 
of this treatment on the survival was evaluated by LDH 
assay. We confirmed that the cell damage increased as the 
concentration of the bevacizumab increased. In the ab-
sence of oxidative stress, RGC-5 cytotoxicity increased 
following treatment with 1 mg bevacizumab, which was 
higher than oxidative stress-induced cytotoxicity (Fig. 2).
Effect of bevacizumab on the expression of VEGF, 
VEGFR-1 and VEGFR-2 in RGC-5 Cells
The expression of VEGF, VEGFR-1, and VEGFR-2 in 
bevacizumab-treated RGC-5 cells was confirmed by West-
ern blot analysis. In addition, the expression of VEGF, 
VEGFR-1, and VEGFR-2 increased as the concentration of 
bevacizumab increased, and the expression of VEGF, 
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VEGFR-1, and VEGFR-2 increased in RGC-5 cells treated 
by H2O2 alone (Fig. 3).
Discussion
A number of recent studies have shown that bevacizum-
ab injection therapy in the vitreous cavity has a remark-
able therapeutic effect in many retinal vascular diseases 
including exudative age-related macular degeneration, dia-
betic retinopathy, and neovascular glaucoma [12,13]. How-
ever, VEGF plays an important role in the neuroprotection, 
development and maturation of the nerve tissues of the 
retina [7]. Normally, VEGF-mediated angiogenesis in the 
human body occurs to protect cells in a hypoxic environ-
ment. The administration of bevacizumab to inhibit 
angiogenesis may cause unintended cytotoxicity and isch-
emic damage [9]. Furthermore, the use of bevacizumab in 
patients with optic nerve weakness, such as glaucoma, is 
likely to cause damage to the retinal ganglion cells, which 
play an important pathophysiological role in glaucoma. In 
glaucoma, there is reduction of the retinal nerve fiber layer 
thickness and loss of retinal ganglion cells [19], and retinal 
ganglion cell damage may cause an irreversible field defect 
or visual loss. 
Although intraocular pressure reduction still remains the 
mainstay of glaucoma therapy, recent studies have sug-
gested that intraocular pressure reduction alone cannot 
prevent irreversible damage to retinal ganglion cells. Neu-
roprotection is a strategy for glaucoma treatment, and a 
number of studies have addressed the factors affecting the 
survival and death of the retinal ganglion cells [20,21]. 
Foxton et al. [15] observed that VEGF-A stimulates the 
survival of retinal ganglion cells in the glaucoma experi-
mental model, and VEGF-A blockade significantly exacer-
bates neuronal cell death. Saint-Geniez et al. [8] reported a 
reduction in retinal ganglion cell thickness when VEGF 
expression was suppressed. 
In this study, we investigated the effects of bevacizumab 
concentration on RGC-5 cell survival under oxidative 
stress. We found that cytotoxicity increased when bevaci-
zumab was applied to the differentiated RGC-5 cell line, 
and cell damage increased with increasing bevacizumab 
concentration. In addition, even in the absence of oxidative 
stress, when bevacizumab was applied to the RGC-5 cell 
line, the cytotoxicity of the cell line increased, and was 
greater than that from oxidative stress (Fig. 2). Our results 
confirm that bevacizumab, which is widely used clinically, 
would inhibit retinal ganglion cell survival. In addition, we 
confirmed that VEGF, VEGFR-1, and VEGFR-2 were all 
produced in the RGC-5 cells used in this experiment. 
When bevacizumab and 800 μM H2O2 were simultaneous-
Fig. 3. Western blot analysis of vascular endothelial growth fac-
tor (VEGF), VEGF receptor (VEGFR)-1 and VEGFR-2 in retinal 
ganglion cell (RGC)-5 cells treated with bevacizumab. The ex-
pression of VEGF, VEGFR-1, and VEGFR-2 increased with the 
increase in bevacizumab concentration, and the expression of 
VEGF, VEGFR-1, and VEGFR-2 was increased in RGC-5 cells 
treated with H2O2. 1, control; 2, bevacizumab 1 mg; 3, H2O2 800 
µM; 4, bevacizumab 0.01 mg + H2O2 800 µM; 5, bevacizumab 0.1 
mg + H2O2 800 µM; 6, bevacizumab 1 mg + H2O2 800 µM. 
 β-actin
VEGF-A
VEGFR-1
VEGFR-2 
1 2 3 4 5 6
Fig. 2. Effects of bevacizumab on the survival of retinal ganglion 
cell (RGC)-5 cells under oxidative stress with 800 μM H2O2 for 
24 hours. As the concentration of bevacizumab increases, the 
RGC-5 death rate increases. With the presence of bevacizumab, 
cell death increased without oxidative stress. Values are presented 
as mean ± standard deviation (*values are significantly different 
from the control; p < 0.05 by Mann-Whitney U-test).
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ly treated with RGC-5, cell damage and the expression of 
VEGF in RGC-5 itself was also increased according to the 
increased concentration of bevacizumab.
This study shows that a high concentration of bevaci-
zumab increases cell death in retinal ganglion cells. How-
ever, since this experiment was not performed in vivo, we 
were unable to show different mechanisms and patterns in 
the human body due to interactions with other cells under 
oxidative stress. In the present study, we used the RGC-5 
cell line, which has been reported to be cross-contaminat-
ed with a mouse fibroblast cell line [22]. Furthermore, the 
RGC-5 cell line may not accurately represent the charac-
teristics of all retinal ganglion cells. Therefore, additional 
experiments and studies will be needed to determine 
whether other animal models and primary retinal ganglion 
cells will produce similar results in the future.
This study is expected to provide a basis for the safe and 
effective use of bevacizumab in various ophthalmic dis-
eases including glaucoma. In the future, bevacizumab 
should be used at the minimum concentration that does not 
cause cytotoxicity. In addition, intravitreal injection of 
bevacizumab for the treatment of retinal vascular disease 
often needs to be repeated rather than administered as a 
single treatment. Therefore, studies on the benefits and 
risks of long-term treatment according to the frequency of 
injection are needed to prevent potential adverse effects of 
indiscriminate bevacizumab treatment. In particular, con-
sidering the fact that bevacizumab treatment may have a 
negative effect on eyes with optic nerve damage such as 
glaucoma, treatment should be performed according to in-
dividual characteristics and more attention should be fo-
cused on these conditions. In addition, long-term large-
scale clinical trials and animal models are needed in the 
future to evaluate the efficacy and safety of bevacizumab 
therapy.
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